Roche figures MabThera safe from biosimilars till 2016

Did Roche ($RHHBY) do the right thing when it took a pass on biosimilars? Its rivals' delays in developing copies of the $7 billion blockbuster MabThera, a.k.a. Rituxan, appear to vindicate that decision, Reuters says. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.